Status:
COMPLETED
The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
Procter and Gamble
Aventis Pharmaceuticals
Conditions:
Osteoporosis
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the effectiveness of once weekly risedronate in the prevention and treatment of bone loss in premenopausal and newly menopausal women with breast cancer who ha...
Detailed Description
Breast cancer is a significant public health problem accounting for approximately 30% of new cancers diagnosed annually. Much advancement has been made in the treatment of these cancers which has sign...
Eligibility Criteria
Inclusion
- Pre- and newly postmenopausal (up to 8 years) women ages 18 and older
- Breast cancer treated with chemotherapeutic agents, with or without tamoxifen/aromatase inhibitors
- Negative pregnancy test
Exclusion
- Stage 4 breast cancer
- Any illness or medications known to affect bone metabolism
- History of osteoporosis or history of vertebral or hip fractures
- Kidney stones in the past 5 years
- Active peptic ulcer disease
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2006
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT00118508
Start Date
May 1 2003
End Date
July 1 2006
Last Update
August 13 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh Medical Center (GCRC)
Pittsburgh, Pennsylvania, United States, 15213